Synthetic Cannabinoids: A Pharmacological and Toxicological Overview.
R. Roque-Bravo, Rafaela Sofia Silva, R. Malheiro, Helena Carmo, Félix Carvalho, Diana Dias Da Silva, J. Silva
The Annual Review of Pharmacology and Toxicology August 1, 2022 DOI: 10.1146/annurev-pharmtox-031122-113758 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Key findings | Synthetic cannabinoids produce effects similar to but more intense than cannabis and have dominated the new psychoactive substances market in the United States and Europe over the past decade. The authors argue that rising synthetic cannabinoid-related intoxications and deaths are a major public health concern, and that thorough characterization of their pharmacodynamics and toxicodynamics is needed to understand acute and chronic effects, interpret clinical and pathological findings, and improve risk awareness. |
Abstract
Synthetic cannabinoids (SCs) are a chemically diverse group of new psychoactive substances (NPSs) that target the endocannabinoid system, triggering a plethora of actions (e.g., elevated mood sensation, relaxation, appetite stimulation) that resemble, but are more intense than, those induced by cannabis. Although some of these effects have been explored for therapeutic applications, anticipated stronger psychoactive effects than cannabis and reduced risk perception have increased the recreational use of SCs, which have dominated the NPS market in the United States and Europe over the past decade. However, rising SC-related intoxications and deaths represent a major public health concern and embody a major challenge for policy makers. Here, we review the pharmacology and toxicology of SCs. A thorough characterization of SCs' pharmacodynamics and toxicodynamics is important to better understand the main mechanisms underlying acute and chronic effects of SCs, interpret the clinical/pathological findings related to SC use, and improve SC risk awareness. Expected final online publication date for the Annual Review of Pharmacology and Toxicology, Volume 63 is January 2023. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.
Citations in the library
Cited by 4
- Psychoactive substances: novel molecular insights and therapeutic potential for Alzheimer's disease. Translational neurodegeneration July 25, 2025
- Identifying EEG markers related to acute cannabis consumption: A systematic review. Neuroscience & Biobehavioral Reviews May 1, 2025
- Qualitative and quantitative in silico toxicity profiling of "angel dust": phencyclidine (PCP) analogues as new psychoactive substances (3-HO-PCP, 3-MeO-PCP, 4-MeO-PCP, 3-HO-PCE, 3-MeO-PCE, 4-MeO-PCE). Archives of Toxicology December 8, 2025
- Decoding the Toxicity of Synthetic Cannabinoids: From Receptor Activation to Multiorgan Dysfunction. Medicinal Research Reviews June 24, 2026
Cites 15
- Cannabinoids Elicit Antidepressant-Like Behavior and Activate Serotonergic Neurons through the Medial Prefrontal Cortex Journal of Neuroscience October 24, 2007
- The prevalence of new psychoactive substances in biological material - a three-year review of casework in Poland. Drug Testing and Analysis 2016
- Synthetic Cannabinoids: Psychopharmacology, Clinical Aspects, Psychotic Onset CNS & Neurological Disorders - Drug Targets April 17, 2017
- Positive Allosteric Modulation of the 5-HT1A Receptor by Indole-Based Synthetic Cannabinoids Abused by Humans ACS Chemical Neuroscience April 23, 2020
- The synthetic cannabinoids phenomenon: from structure to toxicological properties. A review Critical Reviews in Toxicology May 27, 2020
and 10 more in the library